Philadelphia College of Osteopathic Medicine Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2018
NCT03352232
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Philadelphia College of Osteopathic Medicine

Active Ingredients

Drugs in Phase 1 Trials (2)

oxygen (1 trial)

th-1 dendritic cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 1)

Stroke (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2